← Ocugen, Inc. (OCGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ocugen, Inc. (OCGN)
Biological Products, (No Diagnostic Substances) · market cap $339M · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Ocugen, Inc. (OCGN) is a clinical-stage biologics company with a pipeline focused on ocular diseases, including a Phase 3 asset (Brimonidine Tartrate) in dry eye, a Phase 3 program (OCU410ST) in Stargardt disease, and a Phase 2 gene therapy (OCU400) in retinitis pigmentosa. The company has a $508M market cap but carries only ~$31.9M in cash — roughly 4.4 months of runway — against annual R&D spend near $40M, making near-term dilution a structural certainty rather than a tail risk.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · OCU400 Low Doseimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Brimonidine Tartrate | Phase 3 | Dry Eye |
| OCU400 Low Dose | Phase 2 | Retinitis Pigmentosa |
| Brimonidine | Phase 2 | Dry Eye |
| OCU410ST | Phase 3 | Stargardt Disease |
Price & technical context
3-month
-33.8%
6-month
-44.1%
12-month
-38.7%
52-wk range
$0.99–$2.48
vs 50-day MA
-18.2%
vs 200-day MA
-33.2%
Realized vol
78.1%
Max drawdown
-60.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OCGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.